NASDAQ: DYAIDyadic International Inc Stock
$2.35-0.03 (-1.26%)
Updated Jun 2, 2023
DYAI Price
$2.35
Fair Value Price
$2.55
Market Cap
$67.71M
52 Week Low
$1.12
52 Week High
$3.56
P/E
-8.39x
P/B
6.27x
P/S
15.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.26M
Earnings
-$8.20M
Gross Margin
25%
Operating Margin
-251.54%
Profit Margin
-251.5%
Debt to Equity
0.19
Operating Cash Flow
-$7M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DYAI Overview
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DYAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DYAI ($2.35) is undervalued by 8% relative to our estimate of its Fair Value price of $2.55 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
DYAI ($2.35) is not significantly undervalued (8%) relative to our estimate of its Fair Value price of $2.55 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DYAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DYAI due diligence checks available for Premium users.
Be the first to know about important DYAI news, forecast changes, insider trades & much more!
DYAI News
Valuation
DYAI fair value
Fair Value of DYAI stock based on Discounted Cash Flow (DCF)
Price
$2.35
Fair Value
$2.55
Undervalued by
8.00%
DYAI ($2.35) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DYAI ($2.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DYAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DYAI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.39x
Industry
11.51x
Market
52.74x
DYAI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.27x
Industry
5.19x
DYAI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DYAI's financial health
Profit margin
Revenue
$978.1k
Net Income
-$956.4k
Profit Margin
-97.8%
DYAI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
DYAI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$12.8M
Liabilities
$2.0M
Debt to equity
0.19
DYAI's short-term assets ($12.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DYAI's short-term assets ($12.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DYAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.2M
Investing
$2.8M
Financing
$0.0
DYAI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DYAI vs Biotech Stocks
Dyadic International Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.